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Background and aims: A short-interval, two-stage approach termed associating liver 
partition and portal vein ligation for staged hepatectomy (ALPPS) increases the number 
of patients with extensive malignant disease of the liver and a small future liver remnant 
(FLR) that can undergo liver resection. While this approach results in accelerated liver 
hypertrophy of the FLR, it remains unknown whether this phenomenon is restricted to 
liver parenchymal cells. In the current study, we evaluated whether ALPPS alters the 
immunological composition of the deportalized lobe (DL) and the FLR.
Methods: In this prospective, single-center study, liver tissue from the DL and the FLR 
were collected intra-operatively from adult patients undergoing ALPPS for their liver 
metastases. The extent of hypertrophy of the FLR was determined by volumetric helical 
computed tomography. Flow cytometry and histological analyses were conducted on 
liver tissues to compare the frequency of several immune cell subsets, and the architec-
ture of the liver parenchyma between both stages of ALPPS.
results: A total of 12 patients completed the study. Histologically, we observed a patchy 
peri-portal infiltration of lymphocytes within the DL, and a significant widening of the liver 
cords within the FLR. Within the DL, there was a significantly higher proportion of B cells 
and CD4+ T cells as well innate-like lymphocytes, namely mucosa-associated invariant T 
(MAIT) cells and natural killer T (NKT) cells following ALPPS. In contrast, the frequency of 
all evaluated immune cell types remained relatively constant in the FLR.
Abbreviations: ALPPS, associating liver partition and portal vein ligation for staged hepatectomy; CRLM, colorectal liver 
metastases; DL, deportalized lobe; FLR, future liver remnant; POLF, postoperative liver failure; MAIT, mucosa-associated 
invariant T cell.
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inTrODUcTiOn
Surgical resection remains the only curative treatment option 
for patients with primary or metastatic malignancies of the liver 
(1–3). Recently, an innovative procedure termed Associating 
Liver Partition and Portal vein ligation for Staged hepatectomy 
(ALPPS) has demonstrated an accelerated hepatocyte regenera-
tion capable of providing good synthetic liver function in patients 
with a high tumor load and a very small future liver remnant 
(FLR). However, to date, it remains unknown whether regenera-
tion of the immunological components of the liver also occurs 
together with the rapidly expanding FLR. Such knowledge is 
essential to understand the regenerative processes associated with 
ALPPS and support its utilization.
With extensive intrahepatic tumor involvement present in 
up to 45% of resectable cases (4, 5), the safety of resection is 
dependent upon the volume and function of the FLR (6). Patients 
with inadequate FLR volume and/or function are more likely to 
experience postoperative liver failure (POLF) and may have an 
elevated mortality risk (7, 8). Strategies to increase the FLR prior 
to hepatic resection have typically focused on the manipulation 
and redirection of portal blood flow by portal vessel occlusion 
(5, 8, 9). These techniques allow patients with unresectable dis-
ease to potentially undergo a major liver resection with a reduced 
risk of POLF (4, 10–12).
Recently, a short-interval, two-stage approach has been pro-
posed as a viable alternative to portal vein embolism (PVE) in 
order to rapidly increase the FLR volume in patients with exten-
sive malignant disease in the liver and to remove the macroscopic 
disease within a short period of time (13–16). Initially, an open 
right portal vein ligation with in situ splitting of the liver paren-
chyma is performed, while at the same time, the FLR is cleared of 
metastases as needed. Following a short interval, a second stage 
is performed to complete the hepatectomy. The ALPPS procedure 
has been demonstrated to produce accelerated FLR hypertrophy 
in patients with very small FLR volumes [defined as a liver rem-
nant to body weight ratio (LR/BW) of ≤0.5%] (16–20). Moreover, 
this technique allows for the removal of the hepatic tumor bur-
den in a shorter timeframe compared to conventional surgical 
approaches. It also increases the number of patients who can suc-
cessfully undergo both stages of the procedure. While previous 
studies have generally reported positive clinical experiences with 
the ALPPS approach (18–21), demonstrating rapid hepatocyte 
regeneration and good synthetic liver function, little is known 
about the implications of the accelerated liver hypertrophy on 
the resident immune cells present in the liver. Moreover, despite 
the demonstrated hypertropy following the first stage of ALPPS, 
it remains unknown whether this phenomenon is restricted to 
parenchymal cells, or whether resident or recruited immune cell 
populations will also expand in size in response to this two-stage 
resection procedure.
Given the importance of the immune system in protecting 
against infection and cancer development, and in regulating 
liver repair mechanisms (22–25), understanding how the rapid 
hypertrophy of the liver affects the immunological content of the 
liver is of up most importance. More specifically, whether hepatic 
immune cells of normal liver are present within the FLR and 
the FLR will remain immunologically competent following the 
second stage of the ALPPS procedure are essentially unexplored. 
In the current study, we have enumerated, for the first time to our 
knowledge, various hepatic immune cell types after the first and 
second stage of the ALPPS procedure. Our study demonstrates 
that while moderate immunological changes occur in the DL, the 
immune constituents of the FLR appear relatively unaltered by 
the ALPPS procedure.
MaTerials anD MeThODs
study Design and setting
This was a prospective, single-center study conducted at the 
University Hospital (UH), London Health Sciences Centre 
(LHSC) in London, ON, Canada. Human tissue samples were 
collected after obtaining written consent from patients under-
going ALPPS at UH. All surgeries were performed by a single 
hepatobiliary surgeon (RH-A).
Ethics approval for this study was obtained from the Western 
University Research Ethics Board for Health Sciences Research 
Involving Human Subjects (Approval number: REB104571), the 
Lawson Health Research Institute (R-13-490), and the Western 
University Department of Pathology (TA-830).
Patients
All consenting patients, aged 18 and older, with a diagnosis of 
colorectal liver metastases (CRLM), primary hepatocellular car-
cinoma, or cholangiocarcinoma, who were admitted to the UH 
for the ALPPS operation between April 1, 2014 and September 1, 
2015, were included in this study (18, 20). Candidates were 
considered for the ALPPS procedure if they met the following 
inclusion criteria: technically feasible right trisectionectomy for 
high liver tumor load; an FLR volume of less than 30%; and the 
availability of a preoperative computed tomography (CT) scan 
volumetry.
Patients who were younger than 18 or older than 75 were 
excluded from this study. Additional exclusion criteria were 
immunodeficiency, concomitant immunosuppressive therapy, 
pregnancy, a Do-Not-Resuscitate (DNR) status, an ASA risk score 
conclusion: Our results provide the first description of the immunological composition 
of the human liver following ALPPS. We show that following the ALPPS procedure, while 
the immune composition of the FLR remains relatively unchanged, there is a moderate 
increase in several immune cell populations in DL. Overall, our results support the con-
tinued utilization of the ALPPS procedure.
Keywords: liver metastases, alPPs, hepatectomy, liver regeneration, flow cytometry, immunophenotyping
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of 3 or higher, an Eastern Cooperative Oncology Group (ECOG) 
score of 2 or higher, a period of less than 6 weeks between preop-
erative systemic chemotherapy and surgery, disease progression 
despite chemotherapy, extrahepatic metastases (e.g., peritoneal, 
pulmonary, bone marrow, or brain) detected preoperatively or 
intra-operatively at the time of surgery, tumor involving the left 
portal or left hepatic veins, preoperative biliary drainage or portal 
vein obstruction, preoperative signs of systemic or biliary infec-
tion (cholangitis), ascites detected via ultrasonography, end-stage 
liver disease, and chronic kidney disease.
Surgical Technique
A general laparotomy was performed to rule out extrahepatic 
disease (18–20). The liver was fully mobilized from the retro-
hepatic inferior vena cava. An intraoperative ultrasound was 
performed to assess the technical resectability and for the pres-
ence of metastases within the FLR. Once the FLR was cleared 
of metastases by wedge resections, the right portal vein was 
identified and ligated while preserving the hepatic arterial flow 
and biliary drainage of the deportalized liver (DL). The transec-
tion lines were placed to the right of the falciform ligament, and 
complete partition of the liver was performed identifying the 
right hilar plate. After sufficient hypertrophy of the FLR was 
obtained (generally within 7–10  days), the right trisectionec-
tomy was completed by a transection of the right hilar plate, 
as well as the right and middle hepatic veins followed by the 
removal of the DL.
Volumetric Assessment of Hepatic Hypertrophy
All patients underwent volumetric helical CT estimation of their 
liver volumes before the first and second stages of ALPPS, as per 
the technique of Farges et al. (10). Measurements were performed 
for the whole liver, as well as for the right extended liver (includ-
ing segment 4) and the FLR. The FLR volume was considered to 
be the volume of the left lateral sector (segments 2 and 3). The 
estimated rate of the future functional liver remnant volume 
(%FFLR) was calculated after assuming that the density of the 
liver was close to 1 by using the following formula: %FFLR = (left 
liver volume × 100)/(total liver volume − tumor volume) (18–20).
Isolation of Non-Parenchymal Hepatic Mononuclear 
Cells
To obtain non-parenchymal hepatic mononuclear cells 
(HMNCs), samples of liver tissues (range: 0.1–2 g) were collected 
from the DL and the FLR during both stages of the ALPPS opera-
tion. Freshly isolated tissue was pressed through a 40-μm nylon 
mesh, and the resulting homogenate was washed in cold PBS, 
resuspended in a 33.75% Percoll PLUS solution (GE Healthcare 
Bio-Sciences), and spun at 700 × g for 12 min at room tempera-
ture. The supernatant was discarded, and the pelleted cells were 
resuspended in 2.5% Fetal Calf Serum (FCS) in PBS. Cells were 
counted using a hemocytometer and resuspended to a concentra-
tion of 10 × 106 cells/mL.
Flow Cytometry
Freshly isolated, untreated HMNCs (1  ×  106 cells/tube) were 
washed with cold staining buffer (PBS + 2.5% FCS) and stained 
with diluted fluorescently labeled monoclonal antibodies (mAbs) 
for the detection of different immune cell types. Cells were 
stained with various combinations of mAbs to CD3, CD4, CD8, 
TCR γδ, CD56, TCR Vα24, CD11b, CD14, CD19, CD33, CD68, 
CD161, and TCR Vα7.2, for the enumeration of various immune 
cell subsets, including T cell subsets [e.g., CD4+, CD8+, mucosa-
associated invariant T (MAIT) cells, iNKT, and γδ T cells], NK 
cells, B cells, myeloid cells, and myeloid-derived suppressor cells 
(Table S1 in Supplementary Material). Specific combinations of 
mAbs were diluted in staining buffer, and the cells were stained at 
4°C for 30 min in a volume of 100 μL. Cells were then washed twice 
with 2 mL staining buffer and incubated with 7-AAD (Table S1 
in Supplementary Material) for 5 min. Dead cells were excluded 
from analysis by gating on 7-AAD− cells. Flow cytometry was 
performed using a BD FACSCanto II flow cytometer. A minimum 
of 200,000 events were recorded, and the results were analyzed 
using FlowJo software (Treestar, Ashland, OR, USA).
histological staining and assessment
Staining
Liver tissue samples from the DL and the FLR at Stages 1 and 2 
of ALPPS (1–2 g) were fixed in 10% neutral buffered formalin, 
embedded in paraffin, sectioned, and stained with hematoxylin 
and eosin (H&E), or reticulin. For the assessment of the prolif-
erative index, Ki-67 immunohistochemical staining was applied, 
and an avidin–biotin–peroxidase complex immunohistochemi-
cal method was performed for antigen retrieval. The primary 
anti-Ki-67 antibody (clone MIB-1) was purchased from DAKO, 
Glostrup, Denmark.
Assessment
Sections were examined by a board-certified pathologist 
specializing in liver diseases (JP), who was also blinded to the 
study design, procedure stage (stage 1 vs. 2), as well to the liver 
section from where the tissue was isolated (DL vs. FLR). Ten 
high-powered visual fields (40×; field diameter 0.55 mm) were 
examined. Photomicrographs were taken for quantification of the 
Ki-67 proliferation rate.
statistical analysis
All statistical analyses were performed using GraphPad Prism 
version 5.03 (GraphPad, La Jolla, CA, USA). Differences between 
the groups were assessed using the Wilcoxon matched-pairs 
signed rank test or a Chi-square test for continuous and categori-
cal variables, respectively. In all analyses, a value of p ≤ 0.05 was 
considered statistically significant.
resUlTs
accelerated liver hypertrophy in the Flr
A total of 18 patients were enrolled in the study. Due to peritoneal 
carcinomatosis (n =  1) or the development of excessive tumor 
burden in the FLR (n =  4), a total of five patients enrolled in 
the study were precluded from undergoing stage 1. An additional 
patient, who underwent stage 1, was excluded from the study 
after developing thrombosis of the left portal vein. Figure  1 
shows a flow chart outlining the enrollment of patients in the 
TaBle 1 | Baseline clinical characteristics and outcomes of 12 patients 
undergoing alPPs.
Variable Outcome
Clinical characteristics
Median age, y (±SD) 60 ± 9
Male gender, n (%) 7 (58)
Mean body mass index (±SD) 25 ± 3.3
Charlson comorbidity index 6
Oncological characteristics
Type of primary cancer, n (%)
Colon 4 (33)
Rectum 6 (50)
Other 2 (17)
Synchronous metastases, n (%) 6 (50)
Median number of lesions, n 2
Number of patients receiving preoperative chemotherapy, n (%) 11 (92)
FOLFOX 2 (17)
FOLFIRI 6 (50)
Bevacizumab 6 (50)
Operative characteristics
Synchronous resection, n (%) 7 (58)
Number of patients undergoing simultaneous resection, n (%) 3 (25)
Complications, n (%)
All 7 (58)
Severea 3 (25)
Clinical outcomes
Median volume of FLR pre-ALPPSc (±SEM), % 22 (1.5)
Median volume of FLR post-ALPPSc (±SEM), % 39 (2.7)
Median length of hospital stay, d 18
90-day mortality, n (%) 0 (0)
Recurrenceb (%) 3 (25)
aSevere complications as defined by the Clavien-Dindo scale (>IIIB).
bIncludes local, regional, and distal recurrence.
cExpressed as a percentage of total liver volume.
FigUre 1 | Patient enrollment for this study. The provided flow chart 
outlines at what stages patients were excluded from the study based on the 
defined criteria.
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study. The characteristics of the 12 patients included in our study 
are reported in Table  1. We routinely performed triphasic CT 
scans of the abdomen and pelvis at 3 or 7 days after the first stage 
of the operation on all patients in order to quantify the degree 
of FLR hypertrophy. In Figures  2A,B, we present a series of 
representative CT images (annotated to show the major surgical 
landmarks) for two typical patients at stage 1 (A) and at the time 
of stage 2 (B). These images are representative of what is typically 
observed following the first stage of the ALPPS procedure and are 
summarized numerically in Figure 2C. As depicted in Figure 2C, 
we observed a significant increase in the FLR volume, relative to 
the whole liver, between the first and second stage of the ALPPS 
procedure (from 22 to 39%; p < 0.0001), based on CT volumetry. 
Overall, we demonstrate that there is an accelerated hypertrophy 
of the FLR following the first stage of the ALPPS procedure.
histological Differences within the Dl and 
the Flr During alPPs
We next sought to compare the histopathological differences 
within the DL and the FLR during ALPPS. Representative histo-
logical images are presented in Figure 3. In the first stage, biopsies 
of the DL and the FLR (prior to the performance of the portal vein 
ligation and in situ liver partition) demonstrated minimal portal 
inflammation, dilated portal veins, and scattered neutrophils 
(Figure 3A). The mean Ki-67 proliferation index was less than 
1% in both lobes (Figure 3B). Reticulin staining was performed 
to visualize the reticular fibers comprised of Type III collagen that 
supports the liver architecture, which demonstrated a normal 
hepatic plate thickness for both the DL and FLR (Figure 3C).
In stage 2, biopsies of the DL demonstrated patchy portal 
infiltrate of lymphocytes and eosinophils (Figure 3D). The mean 
Ki-67 proliferation index within the DL (2.4%) was significantly 
higher in stage 2 when compared with stage 1 [<1% (p < 0.001); 
Figure  3E]. Reticulin staining of the DL’s architecture demon-
strated a slight widening of the liver cords within zone 1, but there 
were no changes to zones 2 or 3 (Figure 3F). In contrast, the FLR 
at stage 2 showed portal tracts and central veins that appeared 
normal histologically, with no peri-portal inflammation or lym-
phocytosis (Figure 3D). Moreover, the mean Ki-67 proliferation 
index within the FLR was 3.9%, which was significantly higher 
than that in Stage 1 (<1%; p < 0.01), as well as for the DL at Stage 
1 or 2 (p < 0.01; Figure 3E). Further, within the liver parenchyma, 
reticulin staining revealed that the liver cords were significantly 
wider in the FLR at stage 2 than at stage 1, or when compared to 
the DL at stage 1 or 2 (Figure 3F). The widening of the liver cords, 
as identified by reticulin staining, is in line with the observed 
hypertrophy seen in Figure 2B. Collectively, these results indicate 
that the hypertrophy associated with ALPPS is largely restricted 
to the FLR with minimal proliferation in the DL, a finding that is 
in line with our CT volume measurements (Figure 2C). Overall, 
after the second stage of the procedure, the architecture of the 
FLR showed a generally normal appearance.
immunological Differences between the 
Dl and the Flr During alPPs
We subsequently evaluated the non-parenchymal liver cell popu-
lations in the DL and the FLR using flow cytometry. In the first 
stage, as depicted in Figure  4 and summarized numerically in 
Table 2, we observed no differences in any of the major immune 
cell types, including T cells, B cells, NK cells, and myeloid cells 
FigUre 2 | rapid hypertrophy of the future liver remnant occurs between stages 1 and 2 of the alPPs procedure. In Figure 2, we present a series of 
representative cross-sectional CT images taken at various stages throughout the ALPPS procedure. (a) The burden of malignancy within the liver at the time of 
diagnosis; (B) the magnitude of liver hypertrophy observed following ALPPS Stage 1; and (c) a numerical summary of the change in volume for the FLR (expressed 
as a percentage of total liver volume) pre- and post-ALPPS, as determined by CT volumetry for eight patients.
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when comparing the DL and FLR. Figure 4 depicts the mean fre-
quency of each of the major populations alongside representative 
dot plots for each of the populations. Moreover, when comparing 
the DL and FLR during stage 1, we found only minor differences 
in the frequencies of CD4+ and CD8+ T cells (Figure 5A), and a 
similar CD4:CD8 ratio (Figure 5B). Likewise, we observed little 
differences in the frequency of unconventional T cells subsets 
including, NKT (CD3+CD56+), MAIT (CD3+Vα7.2+CD161+), 
and γδ T cells (CD3+γδ TCR+) (Figure 5C), as well as the myeloid 
subsets including Kupffer cells (CD14+CD68+) and monocytes/
macrophages (CD14+CD68−CD11b+/−) when comparing the DL 
to the FLR (Figure 5D). Representative dot plots for each of the 
populations are shown below the appropriate bar graph.
In the second stage, the proportions of the majority of the 
evaluated immune cells did not change in the FLR (Figure 4 and 
Table 2). In contrast, in the second stage, we observed a general 
increase in many of the major immune cells in the DL (Figure 4; 
Figures 5A–D; Table 2). Specifically, we see a significant increase 
in CD4+ T cells, NKT cells, MAIT cells, Kupffer cells, and B cells, 
as well as a trending increase in γδ T cells and macrophages/
monocytes within the DL (Figures  5A–D; Table  2). Overall, 
we found that while the immunological composition of the 
FLR remained largely intact following the ALPPS procedure, 
the DL exhibited moderate increases in several immune cell 
types. Together, these results suggest that the ALPPS induces 
regeneration of hepatocytes as well as the resident immune cells 
in the FLR.
DiscUssiOn
With ALPPS currently being performed in many centers around 
the world, it is important to understand the implications associ-
ated with the accelerated hypertrophy observed in these cases. 
Here, we demonstrate for the first time that the frequency of many 
major immune cell types remains largely unchanged in the FLR, 
whereby the rapid expansion of the FLR occurring between stages 
1 and 2 has not resulted in a dilution of liver resident immune 
cells. Overall, our results provide the first description of the 
immunological ingredients of the human liver following ALPPS.
The accelerated hypertrophy that occurs after ALPPS has 
previously been attributed to the diversion of portal blood flow 
to specific segments, and the abrupt cessation of cross-portal 
circulation into the DL due to parenchymal transection (14, 16, 26). 
However, recent animal studies have suggested the potential 
importance of systemic inflammatory responses in controlling 
liver hypertrophy following ALPPS (27–29). Schlegel et al. (27) 
demonstrated that significant liver hypertrophy was induced by 
parenchymal transection in a mouse model of ALPPS, as opposed 
to portal vein ligation alone. Moreover, selective injury to distant 
organs, such as the kidneys and the spleen, also induced signifi-
cant liver hypertrophy. This suggests that factors secreted into the 
systemic circulation promoted hypertrophy and regeneration 
(27, 29). Indeed, Schlegel et  al. demonstrated that transferring 
the plasma collected from mice undergoing an ALPPS procedure 
into mice undergoing PVE could accelerate the growth of the 
FigUre 3 | histological changes associated with alPPs at stages 1 and 2 in the Dl and Flr. In Figure 3, we present a series of representative 
histopathological images for tissues taken at stages 1 and 2. Samples were taken from both the DL and FLR of patients undergoing ALPPS. (a) Collected tissues 
were stained with hematoxylin and eosin (H&E), and the general histopathology of the DL and FLR sections were assessed at stage 1; (B) Tissue samples were 
collected from the DL and FLR at stage 1 and immunostained with Ki-67 to determine basal proliferation in the different liver sections; (c) Reticulin staining of 
samples obtained from the DL and FLR at stage 1; (D) Collected tissues were stained with hematoxylin and eosin (H&E), and the general histopathology of the DL 
and FLR sections were assessed at stage 2; (e) Tissue samples were collected from the DL and FLR at stage 2 and immunostained with Ki-67 to determine the 
overall level proliferation in the different liver sections; and (F) Reticulin staining of samples taken from the DL and FLR at stage 2. The presented histology is 
representative of eight patients undergoing ALPPS, for which histological scoring was performed. Scoring was performed by a board-certified pathologist, and the 
summary results provided in the text.
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FLR to levels similar to those observed following ALPPS (27). 
Together, these observations highlight the important interplay 
that occurs between the immune system and the parenchymal 
cells of the liver during the process of liver hypertrophy. Despite 
this observed cross-talk between the immune system and paren-
chymal regeneration, the impact of ALPPS on hepatic immune 
cells has remained largely unexplored.
With the ALPPS procedure able to successfully augment the 
size of the FLR in a relatively short-time period, it is important 
to understand whether this rapid hypertrophy alters the distribu-
tion and composition of the immune cell populations in the liver. 
Moreover, the liver is a rich source of innate and adaptive immune 
cells (24, 25, 30–32), which provide immune surveillance against 
infection and cancer (33). Furthermore, it has been previously 
shown that the immune system regulates the repair and regenera-
tion processes of the hepatic parenchyma upon injury (22, 34–36). 
Therefore, it is important to understand the impact of ALPPS on 
these populations (23, 37). Specifically, in our current study, we 
demonstrated that the immune composition of the FLR is largely 
the same before and after the ALPPS procedure, despite the rapid 
expansion of the FLR. Importantly, not only did the frequency of 
various immune cell types not decrease, there was also no sub-
stantial increase in the FLR between stages 1 and 2. Specifically, 
there were no significant increases in any of the evaluated immune 
cell types in the FLR, a finding that suggests uniform immune cell 
regeneration. This is important as an increase in the frequency of 
any one or more immune cell populations may indicate immune 
activation, potentially inducing inflammation, which may in turn 
compromise the function of the FLR. However, this suggestion 
poses a paradox that is the inflammatory process or products may 
be required for the rapid growth of the FLR, as was suggested by 
Schlegel and others (27, 34, 38). In contrast to the FLR, in the 
DL, we observed a generalized but moderate increase in many of 
the evaluated immune subsets, which may, at least theoretically 
at this point, contribute to the inflammatory signals thought to 
drive rapid hypertrophy of the FLR. This is currently a subject 
TaBle 2 | Mean frequencies of major immune cell populations 
(expressed as a percentage of all leukocytes) within the deportalized 
lobe (Dl) and the future liver remnant (Flr) during alPPs.
immune 
markers
cell  
type
Dl Flr
stage  
1
stage  
2
p  
Value
stage  
1
stage  
2
p 
Value
CD3+ T cells 19.9 27.67 0.11 20.22 19.15 0.38
CD19+CD3− B cells 2.92 5.35 0.016 1.46 2.42 0.69
CD3−CD56+ NK cells 11.16 15.21 0.375 11.10 16.57 0.163
CD11b+ Myeloid 
cells
57.4 40.54 0.047 59 42.16 0.22
Comparison between stages 1 and 2 was made by a Wilcoxon matched-pairs signed 
rank test.
FigUre 4 | comparison of major immune cell populations within the Dl and Flr at stages 1 and 2 of alPPs. The frequency of various immune subsets 
was determined by a flow cytometric analysis of non-parenchymal hepatic mononuclear cells isolated from tissue samples collected at stage 1 and 2 from the DL 
and FLR. A series of pie charts outlining the average proportion of T cells (CD45+CD3+), B cells (CD45+CD3−CD19+), NK cells (CD3−CD56+), and myeloid cells 
(CD45+CD11b+). All populations were gated off total CD45+ hematopoietic cells. Representative dot plots depicting the gating scheme for each of the major immune 
populations were included.
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of investigation in our laboratory. Moreover, although we only 
see moderate changes in the frequency of immune cell types in 
the DL and FLR following ALPPS, we do not currently know 
what impact this rapid expansion has had on the functionality 
of these immune populations. Indeed, it would be of interest for 
future studies to evaluate the differentiation stage of the expanded 
Kupffer cells or the immunological functionality of the expanded 
MAIT cells seen in the DL following stage 2.
The underlying reason for applying radical resection is to 
reduce or eliminate the tumor burden within the liver. Had a 
decrease been shown for immune cell populations in the FLR, 
one would have wondered whether this would increase the risk 
of tumor recurrence or infection due to diminished immune 
surveillance in this region. Indeed, many immune cell types 
implicated in tumor surveillance are abundant in the liver.
Comprising up to 10% of the total cell population within 
the liver (32), lymphocytes, including both T cell subsets such 
as CD8+ Cytotoxic T lymphocytes, NKT cells, and MAIT cells, 
as well as non-T cell subsets (e.g., NK cells and B cells) are 
particularly abundant within the liver (39, 40). Importantly, 
there was no decrease in the frequency of any of the afore-
mentioned populations in the FLR. Interestingly, we also found 
a mild increase in many of these populations in the DL when 
comparing their frequencies between stages 1 and 2. While 
unknown, the expansion of these populations may be due to 
the reduced blood flow to the region. Indeed, previous studies 
have demonstrated that many immune cell subsets are remark-
ably sensitive to hypoxia (41–43). Moreover, the proportions 
of CD4+ T cells, NKT cells, MAIT cells, B cells, and Kupffer 
cells increased significantly within the DL following ALPPS. 
Therefore, it remains likely that the activation of these immune 
cells and the release of soluble inflammatory products in the 
DL region may contribute to the stimulating factors required 
for facilitating the rapid hypertrophy of the FLR, as has been 
previously suggested by others (27). Interestingly, we observed 
FigUre 5 | a comparison of various immune cell subsets within the Dl and Flr at stages 1 and 2 of alPPs. The frequency of various immune subsets 
was determined by a flow cytometric analysis of non-parenchymal hepatic mononuclear cells isolated from tissue samples collected at stage 1 and 2 from the DL 
and FLR. (a) The frequency of conventional CD4+ (CD45+CD3+CD4+) and CD8+ (CD45+CD3+CD8+) T cells; (B) The ratio of CD4:CD8 T cells; (c) The frequency of 
the unconventional NKT (CD45+CD3+CD56+), γδ (CD45+CD3+γδ TCR+), and MAIT (CD45+CD3+Vα7.2+CD161+) T cells subsets; and (D) myeloid cells including 
Kupffer cells (CD45+CD14+CD68+) and macrophages/monocytes (CD14+CD68−CD11b+/−). Results are the mean ± SEM for a series of six patients undergoing 
ALPPS. Statistical differences were determined by a Wilcoxon matched-pairs signed rank test *p < 0.05.
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a modest, although non-significant, increase in NK cells in the 
FLR following the second stage of the procedure. Although many 
studies have examined the role of NK cells during liver regenera-
tion in animal models, it is still unclear whether they potentiate 
or suppress hepatic growth (35, 36, 44–47). Graubardt et  al. 
demonstrated that NK cells support hepatocyte proliferation in 
a mouse model of partial hepatectomy (35). However, Wei et al. 
observed an inhibition of liver regeneration by NK-cell-induced 
production of TNF-α in a mouse model of CCl4-induced liver 
injury (44). Additionally, Vujanovic et al. determined that NK 
cell populations increased significantly during the early phase 
of liver regeneration following partial hepatectomy in rats (36). 
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However, their activity was functionally suppressed, and this 
finding potentially represented a regulatory mechanism for 
which liver regeneration could be enhanced (36). Interestingly, 
the mechanism by which ALPPS causes rapid hypertrophy of the 
FLR may be applicable to other models where rapid hypertrophy 
may be advantageous. Indeed, in one previous report, the size of 
the transplanted liver graft was successfully augmented through 
the use of an ALPPS-like procedure in a patient undergoing 
liver transplantation (48).
Overall, we have demonstrated that following ALPPS, there 
is rapid hypertrophy accompanied by the presence of all major 
immune cell types in the regenerated liver. While subtle changes 
to various immune populations in the FLR were observed, none 
reached statistical significance. Future studies with a larger sam-
ple size are required to validate these changes and to explore the 
functional capacities of these altered hepatic immune cell types 
in the FLR between stages 1 and 2 of ALPPS.
cOnclUsiOn
We demonstrate the histopathological and immunological 
changes that occur within the DL and the FLR following ALPPS 
in humans for the first time. Our results demonstrate that the 
liver expansion occurring between stages 1 and 2 of the ALPPS 
procedure is not only restricted to parenchymal cells but also 
occurs in resident hepatic immune cells. Together, our results 
demonstrate that the ALPPS procedure remains a viable alterna-
tive to conventional resection techniques by promoting the rapid 
expansion of the FLR, while allowing the liver to remain immu-
nologically competent. Together, these findings support ALPPS 
as an innovative surgical option for patients with extensive liver 
malignancy and a small FLR.
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